샘플 요청 목록

 카트 문의
시장보고서
상품코드
1760899

세계의 성병(STD) 치료제 시장

Sexually Transmitted Diseases (STDs) Drug
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 196 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

성병(STD) 치료제 세계 시장은 2030년까지 1,236억 달러에 도달

2024년에 722억 달러로 추정되는 성병(STD) 치료제 세계 시장은 2024-2030년 분석 기간에 CAGR 9.4%로 성장하여 2030년에는 1,236억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 HPV는 CAGR 9.8%를 나타내고, 분석 기간 종료시에는 743억 달러에 이를 것으로 예측됩니다. 클라미디아 분야의 성장률은 분석 기간중 CAGR 8.7%로 추정됩니다.

미국 시장은 추정 191억 달러, 중국은 CAGR 12.9%로 성장 예측

미국의 성병(STD) 치료제시장은 2024년에 191억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 274억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 12.9%로 예상됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 6.9%와 7.2%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 7.2%를 보일 전망입니다.

세계 성병 치료제 시장 - 주요 동향 및 촉진요인 정리

성병(STD) 치료제는 무엇이며, 왜 현대 건강관리에서 중요한가?

성병(STD)은 성행위감염증(STI)이라고도 하며, 주로 성 접촉을 통해 감염되는 감염병입니다. 일반적인 성병에는 클라미디아, 임질, 매독, 성기 포진, 인유두종 바이러스(HPV), HIV/AIDS 등이 있습니다. 이러한 감염증의 치료에는 항생제, 항바이러스제, 항진균제, 항레트로바이러스제 등 다양한 의약품이 사용되며, 각 의약품은 특정 병원체 및 질병과 관련된 증상을 표적으로 삼도록 설계되어 있습니다. 성병 치료제는 이러한 감염병을 관리하고, 감염률을 낮추며, 불임, 장기 장애, 다른 감염증의 발병률 증가와 같은 장기적인 건강 합병증을 예방하는 데 중요한 역할을 하고 있으며, 성병의 적시에 효과적인 치료는 이러한 질병의 확산을 억제하고 공중 보건 성과를 개선하는 데 필수적입니다.

세계 성병 치료제 시장은 감염률 증가와 성 건강에 대한 인식이 높아짐에 따라 그 중요성이 점점 더 커지고 있습니다. 세계보건기구(WHO)는 전 세계적으로 매일 100만 명 이상이 STI에 감염되는 것으로 추정하고 있으며, 효과적인 치료 및 예방 전략의 시급한 필요성을 강조하고 있습니다. 이 시장은 또한 고위험 행동의 확산, 불충분한 성 건강 교육, 특정 지역의 의료 서비스에 대한 접근성 제한에 의해 주도되고 있습니다. 또한, 보다 효과적이고 내성이 적은 약물을 개발하기 위한 연구 개발이 진행되고 있는 것도 시장 확대에 기여하고 있습니다. 새로운 약제 내성 박테리아와 바이러스 균주의 출현으로 혁신적인 치료법 개발이 그 어느 때보다 중요해지고 있습니다. 그 결과, 성병 치료제 시장은 전 세계 성병의 부담과 싸우고 전 세계 성 건강을 증진하는 데 있어 매우 중요한 역할을 하게 될 것입니다.

기술 및 과학 발전은 성병 치료제 개발을 어떻게 형성하고 있는가?

기술 및 과학의 발전은 성병 치료제의 개발 및 효능을 크게 향상시켜 부작용이 적고 효과적인 치료법을 개발할 수 있게 해주고 있습니다. 이 분야의 주요 발전 중 하나는 약제 내성 병원체를 표적으로 하는 차세대 항생제 및 항바이러스제 개발입니다. 약제 내성은 임질이나 매독과 같은 세균성 성병 치료에 있어 큰 도전이 되고 있습니다. 다제내성 균주의 출현으로 기존 항생제의 대부분이 효과가 없어지고 있으며, 내성 메커니즘을 극복할 수 있는 새로운 약물 계열의 개발이 필요하게 되었습니다. 연구자들은 내성균에 대한 약물의 침투성과 효능을 향상시키기 위해 새로운 항생제 조합과 나노입자 기반 제형과 같은 새로운 약물 전달 시스템을 모색하고 있습니다. 이러한 혁신은 성병 치료의 효과를 유지하고 내성 감염의 확산을 억제하는 데 매우 중요합니다.

또 다른 큰 발전은 성병 치료에 있어 표적 치료와 개인 맞춤형 의료 접근법의 활용입니다. 다양한 감염성 질환의 분자 메커니즘에 대한 이해가 깊어짐에 따라 연구자들은 병원균의 복제 및 생존에 관여하는 단백질과 경로를 특이적으로 표적으로 삼는 약물을 개발하고 있습니다. 예를 들어, HIV의 프로테아제 억제제나 헤르페스의 헬리카제 억제제와 같이 특정 바이러스 효소의 활성을 억제하는 표적 항바이러스 치료제는 보다 효과적이고 집중적인 치료 옵션을 제공합니다. 또한, CRISPR-Cas9와 같은 유전자 편집 기술의 발전은 숙주 세포 내 바이러스 DNA를 직접 표적화하여 변형시킴으로써 바이러스 감염을 치료할 수 있는 새로운 가능성을 열어주고 있습니다. 이러한 기술은 아직 연구 초기 단계에 있지만, HIV, 헤르페스 등 만성 바이러스 감염증의 치료 상황을 바꿀 수 있는 잠재력을 가지고 있습니다.

HIV 예방 및 치료용 카보테그라비르와 같은 장기지속형 주사제는 투여 빈도를 매일에서 매월 또는 분기별로 줄일 수 있어 환자들의 치료 요법 순응도를 높일 수 있습니다. 수 있습니다. 클라미디아에 대한 아지트로마이신과 같은 특정 세균성 성병에 대한 단회 투여 치료는 특히 의료 접근성이 제한적인 지역에서 감염증을 관리하는 데 편리하고 효과적인 솔루션을 제공합니다. 이러한 기술적, 과학적 발전은 성병 치료의 효과와 편의성을 향상시킬 뿐만 아니라, 의료진이 이용할 수 있는 치료 옵션의 범위를 넓혀 성병에 걸린 사람들에게 보다 종합적이고 맞춤 치료를 제공할 수 있는 길을 열어주고 있습니다.

다양한 지역과 인구에서 성병 치료제의 채택을 촉진하는 요인은 무엇인가?

성병 치료제의 채택은 감염률 증가, 인식 개선 및 검사, 세계 보건 이니셔티브의 시행 등 몇 가지 중요한 요인에 의해 촉진되고 있습니다. 주요 촉진요인 중 하나는 특히 젊은 성인과 고위험군의 성병 발병률이 전 세계적으로 증가하고 있다는 점입니다. 성 파트너 증가와 피임기구의 일관성 없는 사용과 같은 성행동의 변화가 성병의 확산에 기여하고 있습니다. 이에 따라 의료 서비스 제공업체와 공중 보건 기관은 감염 확산을 억제하고 의료 시스템에 대한 부담을 줄이기 위해 효과적인 성병 치료제의 사용을 우선시하고 있습니다. 정기적인 성병 검사에 대한 인식과 수용도가 높아지면서 감염의 조기 진단과 치료를 지원하고, 성병 치료제에 대한 수요 증가로 이어지고 있습니다. 이러한 추세는 특히 북미와 유럽과 같은 선진국에서 두드러지게 나타나고 있으며, 광범위한 검진 프로그램과 인식 개선 캠페인을 통해 개인들이 적시에 치료를 받도록 독려하고 있습니다.

성병 치료제의 채택을 촉진하는 또 다른 중요한 요소는 성병의 확산을 줄이고 치료 접근성을 개선하기 위한 세계 보건 이니셔티브의 실행입니다. 90-90-90' 목표와 같은 이니셔티브를 통해 성병의 확산을 막기 위해 적극적으로 노력하고 있습니다. 이러한 프로그램은 검사, 치료, 예방의 중요성을 강조하고, 특히 중저소득 국가에서 치료 접근성을 개선하기 위한 자금과 자원을 제공합니다. 그 결과, 더 많은 사람들이 진단 서비스와 생명을 구하는 약품에 접근할 수 있게 되어 이들 지역에서 성병 치료제의 보급에 기여하고 있습니다. 또한, 제네릭 의약품의 출시로 인해 치료 비용이 저렴해져 자원이 부족한 환경에서 치료제의 채택을 더욱 촉진하고 있습니다.

또한, HIV 예방을 위한 노출 전 예방약(PrEP)과 같은 예방 요법에 대한 관심이 높아지면서 성병 치료제에 대한 수요가 증가하고 있으며, HIV 감염을 예방하기 위해 항레트로바이러스제를 정기적으로 복용하는 PrEP는 고위험군 사이에서 효과적인 예방 전략으로 인기를 끌고 있습니다. PrEP가 신규 HIV 감염을 감소시키는 데 성공하면서 많은 국가에서 PrEP를 채택하고 있으며, 제약사들은 효과와 편의성을 개선한 새로운 PrEP 제제를 개발하여 이에 대응하고 있습니다. 이러한 예방 노력은 HIV에 국한되지 않고 백신과 예방 치료제 개발을 통해 다른 성병에도 적용되고 있습니다. 예를 들어, 생식기 사마귀와 자궁경부암과 관련된 특정 인유두종 바이러스의 균주를 예방하는 HPV 백신은 예방책으로 널리 사용되고 있습니다. 이러한 예방 전략은 기존의 치료 접근법을 보완하고, 감염 발생률을 낮추며, 더 나은 성 건강 결과를 촉진함으로써 전체 성병 치료제 시장의 성장에 기여하고 있습니다.

세계 성병 치료제 시장의 성장을 주도하는 요인은 무엇인가?

세계 성병 치료제 시장의 성장은 전 세계 감염률 증가, R&D 투자 증가, 약물 내성 대응에 대한 관심 증가 등 여러 요인에 의해 주도되고 있습니다. WHO는 치료 가능한 성병(클라미디아, 임질, 매독, 트리코모나스 등)의 신규 감염자가 연간 3억 7,600만 명에 달할 것으로 추정하고 있습니다. 이러한 감염은 합병증을 유발할 수 있고, 그 부담이 크기 때문에 효과적인 치료에 대한 수요가 증가하고 있습니다. 또한, 헤르페스 및 HIV/AIDS와 같은 바이러스성 성병의 발병률 증가는 시장 성장에 더욱 기여하고 있습니다. 성병 환자 수가 증가함에 따라 의료 제공업체와 정부는 검사 및 치료 서비스에 대한 접근성을 높이기 위해 투자하고 있으며, 이는 성병 치료제에 대한 수요를 증가시키고 있습니다.

시장 성장의 또 다른 주요 촉진요인은 제약회사와 연구기관의 연구개발에 대한 투자 증가입니다. 임질과 같은 세균성 성병의 항생제 내성에 대한 우려가 커지면서 새롭고 효과적인 치료 옵션이 절실히 요구되고 있습니다. 제약사들은 새로운 항생제를 적극적으로 개발하고 내성균에 대응하기 위해 새로운 작용기전을 모색하고 있습니다. 또한, 장기지속형 제제 및 병용요법에 대한 연구는 환자의 순응도를 개선하고 내성 위험을 줄일 수 있는 새로운 치료 옵션을 제공합니다. 현재 진행 중인 헤르페스 및 HIV 백신 연구와 같은 성병 백신 개발도 예방 치료의 범위를 확대하여 시장 개척에 기여하고 있습니다. 또한, 원격 의료 플랫폼 및 재택 검사 키트와 같은 디지털 헬스 기술의 통합은 치료 접근성을 강화하고 조기 진단 및 치료를 촉진하여 전체 성병 치료제 시장의 성장을 뒷받침하고 있습니다.

또한, 성 건강을 개선하고 성병과 관련된 편견을 줄이는 데 중점을 두고 있는 것도 시장 성장을 가속하고 있습니다. 공중보건 캠페인과 옹호 활동으로 정기적인 검진, 안전한 성행위, 적기 치료의 중요성에 대한 인식이 높아지면서 더 많은 사람들이 치료를 받고 있습니다. 이러한 인식의 변화는 특히 감염률이 높은 지역에서 성병 치료제에 대한 수요를 증가시키고 있습니다. 또한, 제네릭 및 일반의약품(OTC) 치료제의 출시로 성병 치료제의 접근성이 향상되고 가격이 저렴해지면서 선진국과 신흥국 모두에서 성병 치료제 시장 개척을 촉진하고 있습니다. 이러한 요인들이 계속해서 세계 헬스케어 환경을 형성함에 따라 성병 치료제 시장은 감염률 증가, 지속적인 연구 개발, 치료 및 예방 옵션에 대한 접근성을 개선하기 위한 전 세계적인 노력 증가로 인해 지속적인 성병 치료제 시장의 성장이 예상됩니다.

부문

질환 유형(HPV, 클라미디아, HIV/에이즈, 임질, 성기 헤르페스, 매독, 기타 질환 유형), 치료법(항생제, 항바이러스제/항 레트로바이러스제, 백신, 기타 치료법)

조사 대상 기업 예(총 46개사)

  • AbbVie, Inc.
  • Bayer Healthcare AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.07.08

Global Sexually Transmitted Diseases (STDs) Drug Market to Reach US$123.6 Billion by 2030

The global market for Sexually Transmitted Diseases (STDs) Drug estimated at US$72.2 Billion in the year 2024, is expected to reach US$123.6 Billion by 2030, growing at a CAGR of 9.4% over the analysis period 2024-2030. HPV, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$74.3 Billion by the end of the analysis period. Growth in the Chlamydia segment is estimated at 8.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$19.1 Billion While China is Forecast to Grow at 12.9% CAGR

The Sexually Transmitted Diseases (STDs) Drug market in the U.S. is estimated at US$19.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$27.4 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.9% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Global Sexually Transmitted Diseases (STDs) Drug Market - Key Trends & Drivers Summarized

What Are Sexually Transmitted Diseases (STDs) Drugs and Why Are They Critical in Modern Healthcare?

Sexually transmitted diseases (STDs), also known as sexually transmitted infections (STIs), are infections that are primarily spread through sexual contact. Common STDs include chlamydia, gonorrhea, syphilis, genital herpes, human papillomavirus (HPV), and HIV/AIDS. The treatment of these infections relies on a range of pharmaceutical drugs, including antibiotics, antivirals, antifungals, and antiretrovirals, each designed to target specific pathogens or symptoms associated with the disease. STD drugs play a crucial role in managing these infections, reducing transmission rates, and preventing long-term health complications such as infertility, organ damage, or increased susceptibility to other infections. Timely and effective treatment of STDs is essential for controlling the spread of these diseases and improving public health outcomes.

The global STD drugs market is becoming increasingly significant due to rising infection rates and growing awareness of sexual health. The World Health Organization (WHO) estimates that over 1 million STIs are acquired daily worldwide, highlighting the urgent need for effective treatment and prevention strategies. The market is further driven by the increasing prevalence of high-risk behaviors, inadequate sexual health education, and limited access to healthcare services in certain regions. In addition, the ongoing research and development efforts to create more effective and less resistant drugs are contributing to the expansion of the market. With the emergence of new drug-resistant strains of bacteria and viruses, the development of innovative therapies is becoming more critical than ever. As a result, the STD drugs market is poised to play a pivotal role in combating the global burden of sexually transmitted infections and promoting better sexual health worldwide.

How Are Technological and Scientific Advancements Shaping the Development of STD Drugs?

Technological and scientific advancements are significantly enhancing the development and efficacy of STD drugs, enabling the creation of more effective treatments with fewer side effects. One of the key advancements in this field is the development of next-generation antibiotics and antivirals that target drug-resistant strains of pathogens. Drug resistance has become a major challenge in the treatment of bacterial STDs such as gonorrhea and syphilis. The emergence of multi-drug-resistant strains has rendered many traditional antibiotics ineffective, necessitating the development of new classes of drugs that can overcome resistance mechanisms. Researchers are exploring new antibiotic combinations, as well as novel drug delivery systems such as nanoparticle-based formulations, to improve drug penetration and effectiveness against resistant bacteria. These innovations are crucial for maintaining the effectiveness of STD treatments and reducing the spread of resistant infections.

Another significant advancement is the use of targeted therapies and personalized medicine approaches in STD treatment. With a deeper understanding of the molecular mechanisms underlying various infections, researchers are developing drugs that specifically target the proteins or pathways involved in the replication and survival of the pathogens. For instance, targeted antiviral therapies that inhibit the activity of specific viral enzymes, such as protease inhibitors for HIV or helicase inhibitors for herpes, are providing more effective and focused treatment options. In addition, advancements in gene editing technologies, such as CRISPR-Cas9, are opening up new possibilities for curing viral infections by directly targeting and modifying viral DNA within host cells. Although these technologies are still in the early stages of research, they hold the potential to revolutionize the treatment landscape for chronic viral infections such as HIV and herpes.

Furthermore, the development of long-acting formulations and single-dose treatments is enhancing patient compliance and convenience. Long-acting injectables, such as cabotegravir for HIV prevention and treatment, offer the potential to reduce the frequency of dosing from daily to monthly or even quarterly, making it easier for patients to adhere to their treatment regimens. Single-dose treatments for certain bacterial STDs, such as azithromycin for chlamydia, provide a convenient and effective solution for managing infections, particularly in regions with limited access to healthcare. These technological and scientific advancements are not only improving the effectiveness and convenience of STD treatments but are also expanding the scope of therapeutic options available to healthcare providers, paving the way for more comprehensive and personalized care for individuals affected by sexually transmitted infections.

What Factors Are Driving the Adoption of STD Drugs Across Different Regions and Populations?

The adoption of STD drugs is being driven by several key factors, including rising infection rates, increased awareness and testing, and the implementation of global health initiatives. One of the primary drivers is the rising incidence of STDs globally, particularly among young adults and high-risk populations. Changes in sexual behaviors, such as increased number of sexual partners and inconsistent use of protection, are contributing to the spread of STDs. In response, healthcare providers and public health organizations are prioritizing the use of effective STD drugs to control the spread of infections and reduce the burden on healthcare systems. The growing awareness and acceptance of regular STD testing are also supporting the early diagnosis and treatment of infections, leading to higher demand for STD drugs. This trend is particularly noticeable in developed regions such as North America and Europe, where extensive screening programs and awareness campaigns are encouraging individuals to seek timely treatment.

Another significant factor driving the adoption of STD drugs is the implementation of global health initiatives aimed at reducing the prevalence of STDs and improving access to treatment. Organizations such as the WHO and UNAIDS are actively working to combat the spread of STDs through initiatives like the Global Health Sector Strategy on Sexually Transmitted Infections and the “90-90-90” targets for HIV treatment and prevention. These programs emphasize the importance of testing, treatment, and prevention, and they provide funding and resources to improve access to care, particularly in low- and middle-income countries. As a result, more people are gaining access to diagnostic services and life-saving medications, contributing to the growing adoption of STD drugs in these regions. Moreover, the increasing availability of generic drugs is making treatment more affordable, further supporting adoption in resource-limited settings.

Additionally, the rising focus on preventive therapies, such as pre-exposure prophylaxis (PrEP) for HIV prevention, is driving demand for STD drugs. PrEP, which involves taking antiretroviral drugs regularly to prevent HIV infection, is gaining popularity as an effective prevention strategy among high-risk populations. The success of PrEP in reducing new HIV infections is encouraging its adoption in many countries, and pharmaceutical companies are responding by developing new PrEP formulations with improved efficacy and convenience. This focus on prevention is not limited to HIV but is also being applied to other STDs through the development of vaccines and prophylactic treatments. For example, the HPV vaccine, which prevents certain strains of the human papillomavirus linked to genital warts and cervical cancer, is being widely adopted as a preventive measure. These preventive strategies are complementing traditional treatment approaches and contributing to the overall growth of the STD drugs market by reducing the incidence of infections and promoting better sexual health outcomes.

What Is Driving the Growth of the Global STD Drugs Market?

The growth in the global STD drugs market is driven by several factors, including rising global infection rates, increasing investments in research and development, and the growing focus on addressing drug resistance. One of the primary growth drivers is the rising prevalence of STDs worldwide. The WHO estimates that there are over 376 million new cases of curable STDs (such as chlamydia, gonorrhea, syphilis, and trichomoniasis) annually. The high burden of these infections, coupled with their potential complications, is driving the demand for effective treatments. Additionally, the increasing incidence of viral STDs such as herpes and HIV/AIDS is further contributing to market growth. As the number of people affected by STDs continues to rise, healthcare providers and governments are investing in expanding access to testing and treatment services, which is boosting the demand for STD drugs.

Another significant driver of market growth is the increasing investment in research and development by pharmaceutical companies and research institutions. With the growing concern over antibiotic resistance in bacterial STDs like gonorrhea, there is a pressing need for new and effective treatment options. Pharmaceutical companies are actively developing new antibiotics and exploring novel mechanisms of action to address resistant strains. Additionally, research into long-acting formulations and combination therapies is providing new treatment options that improve patient adherence and reduce the risk of resistance. The development of vaccines for STDs, such as ongoing research into vaccines for herpes and HIV, is also contributing to market growth by expanding the scope of preventive therapies. Furthermore, the integration of digital health technologies, such as telemedicine platforms and at-home testing kits, is enhancing access to care and facilitating early diagnosis and treatment, supporting the overall growth of the STD drugs market.

Moreover, the focus on improving sexual health and reducing stigma around STDs is driving market growth. Public health campaigns and advocacy efforts are raising awareness of the importance of regular screening, safe sexual practices, and timely treatment, encouraging more people to seek care. This shift in attitudes is increasing the demand for STD drugs, particularly in regions with high infection rates. Additionally, the availability of generic and over-the-counter (OTC) treatments is making STD drugs more accessible and affordable, supporting market growth in both developed and developing regions. As these factors continue to shape the global healthcare landscape, the STD drugs market is expected to experience sustained growth, driven by rising infection rates, ongoing research and development, and increasing efforts to improve access to treatment and prevention options worldwide.

SCOPE OF STUDY:

The report analyzes the Sexually Transmitted Diseases (STDs) Drug market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital Herpes, Syphilis, Other Disease Types); Therapy (Antibiotics, Antivirals / Antiretrovirals, Vaccines, Other Therapies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 46 Featured) -

  • AbbVie, Inc.
  • Bayer Healthcare AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Sexually Transmitted Diseases (STDs) Drug - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of STDs Globally Spurs Demand for Effective Therapeutics
    • Increasing Awareness and Early Diagnosis of STDs Expands Addressable Market for Drug Therapies
    • Rising Government and NGO Efforts for STD Prevention Bodes Well for Market Growth
    • Development of Innovative Antibiotics and Antivirals Propels Market Growth for STD Drugs
    • Focus on Addressing Antibiotic Resistance Issues in STD Treatment Supports Market Expansion
    • Emergence of Vaccines for STDs Creates New Opportunities in the Market
    • Focus on Reducing Stigma and Improving Access to Treatment Propels Market Demand
    • Increased Availability of Over-the-Counter STD Treatment Options Bodes Well for Market Growth
    • Rising Demand for Home-Based and Rapid Diagnostic Kits Supports Growth of STD Drug Market
    • Focus on Digital Health Platforms and Telemedicine for STD Treatment Drives Market Growth
    • Emergence of Long-Acting Injectables and Implants Creates New Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sexually Transmitted Diseases (STDs) Drug Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for HPV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for HPV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for HPV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Chlamydia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for HIV / AIDS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for HIV / AIDS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for HIV / AIDS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Gonorrhea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Genital herpes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Genital herpes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Genital herpes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Syphilis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Antivirals / Antiretrovirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Antivirals / Antiretrovirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Antivirals / Antiretrovirals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • JAPAN
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • CHINA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • EUROPE
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • FRANCE
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 71: France Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: France 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • GERMANY
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Germany 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Germany 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Italy 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Italy 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 89: UK Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: UK 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 92: UK Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: UK 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Spain 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Spain 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Russia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Russia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Rest of Europe 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Europe 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Asia-Pacific 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Asia-Pacific 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Australia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Australia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • INDIA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 128: India Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: India 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 131: India Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: India 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: South Korea 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: South Korea 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Latin America 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Latin America 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Argentina 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Argentina 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Brazil 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Brazil 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Mexico 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Mexico 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Latin America 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Latin America 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Middle East 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Middle East 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Iran 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Iran 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Israel 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Israel 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Saudi Arabia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Saudi Arabia 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: UAE 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: UAE 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Rest of Middle East 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Rest of Middle East 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030
  • AFRICA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Africa 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Africa 15-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제